At the time, how hormones fuelled prostate cancer was still a bit of a mystery. Researchers did not fully understand the mechanism behind prostate cancer’s reliance on testosterone, and some were ...

From 1996, early stage clinical trials in prostate cancer patients led by Professor Judson with pharmacodynamic studies carried out by Dr Florence Raynaud showed that abiraterone did hit the correct ...

The recommended Phase II dose of abiraterone acetate is 1000 mg orally daily in combination with prednisone 5 mg twice daily. Side effects are minimal and mostly associated with secondary ...